clinical trial · NCT02199600
The Medacta International GMK Sphere Post-Marketing Surveillance Study
Medacta International SA·N/A·active not recruiting·n = 500
ArthritisTraumatic ArthritisRheumatoid ArthritisPoly-arthritisAvascular NecrosisGMK Sphere Knee Replacement
brief summary
This is a Post-Marketing Surveillance of GMK Sphere knee prosthesis.
started
Oct 1, 2012
primary completion
Oct 1, 2029
completion
Oct 1, 2029
last updated
Dec 16, 2024
detailed description
The clinical performance of the GMK® Sphere, manufactured by Medacta International, will be evaluated by a multicentre, prospective clinical surveillance study.
The Elective Orthopaedic Centre (EOC), in Epsom, Surrey, will be the study coordinating centre. Four further centres will participate in the clinical study, for five total centres. Each participating centre will recruit approximately 100 patients. Patient recruitment will cease when a cohort of 500 GMK® Sphere knee replacements have been implanted.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol